United States FFPE Tissue Samples for Genomics Study and Analysis Market Size, Share, Growth, and Industry Analysis, By Sample Type (Blocks, Slides, Scrolls, Curls ), By Nucleic Acid Type (Downstream Application) (DNA-based Genomic Analysis Whole Genome Sequencing (WGS) Whole Exome Sequencing (WES) CNV/SNP Analysis qPCR-based Genotyping, RNA-based Genomic Analysis Transcriptome Profiling mRNA Sequencing miRNA Sequencing Gene Fusion Studies ) and Forecast, 2026-2034

United States FFPE Tissue Samples for Genomics Study and Analysis Market Trends

Integration of High-Throughput Sequencing, Multiomics and Archival Tissue

NGS and multiomic workflows are extending the analytical utility of archived FFPE material beyond conventional targeted panels. In a published clinical pathology implementation covering November 2021-April 2025, 623 FFPE specimens underwent metagenomic NGS for pathogen detection, illustrating the feasibility of sequencing preserved tissue in routine workflows. Separately, Tempus reported a data library exceeding 40 million research records, including more than 1.5 million records linked to genomic information and approximately 300,000 records containing genomic and whole-transcriptomic data.

Technology development is moving toward higher-resolution multiomics and broader sequencing coverage. Illumina announced spatial transcriptomics technology capable of cellular-resolution measurements across millions of cells per slide, with a capture area 9 times larger and resolution 4 times greater than existing technologies cited by the company. Tempus also reported that its WGS pilot involving 135 patients achieved greater than 98.9% concordance with traditional molecular methods. These improvements support growing utilization of preserved tissue across cancer genomics, biomarker validation, rare-disease research and translational programs.

United States FFPE Tissue Samples for Genomics Study and Analysis Market Drivers

Expansion of Precision Oncology and Tissue-Based Comprehensive Genomic Profiling

Precision oncology is increasing the analytical value of historical FFPE inventories as laboratories seek molecular information from previously collected tumor specimens. Tempus received FDA approval in May 2026 for a tumor-only indication for its xT CDx, a 648-gene tissue-based NGS assay, eliminating the matched-normal requirement in eligible workflows. Tempus additionally reports more than 1.5 million records combining clinical and genomic information within a database exceeding 40 million research records. Together with WGS studies demonstrating more than 98.9% concordance across a 135-patient pilot, these developments illustrate increasing genomic depth, larger assay panels and broader use of tissue-based molecular profiling.

United States FFPE Tissue Samples for Genomics Study and Analysis Market Restraints

Formalin-Induced Molecular Damage and Variable Nucleic-Acid Quality

FFPE workflows remain constrained by fragmentation, cross-linking, chemical modification and variable fixation conditions that can reduce recoverable DNA and RNA quality. A real-world infectious-pathology investigation nevertheless processed 623 FFPE specimens collected during a roughly 42-month analytical period from November 2021 through April 2025, demonstrating both the utility and workflow complexity of archived specimens. Laboratories frequently require extraction optimization, quality thresholds, orthogonal PCR or sequencing validation and bioinformatics controls; the resulting additional processing can offset portions of the productivity gains created by high-throughput genomic platforms.

United States FFPE Tissue Samples for Genomics Study and Analysis Market Opportunities

Multiomic Profiling Creates New Value from Existing Tissue Archives

Integration of genomics, transcriptomics, methylation and spatial biology provides an opportunity to generate additional molecular information from finite tissue resources. Illumina's announced spatial platform provides cellular resolution across millions of cells per slide, with 9-fold greater capture area and 4-fold higher resolution according to the company, while its planned 2026 5-base workflow targets simultaneous genetic-variant and methylation analysis. Tempus's approximately 300,000 records containing genomic and whole-transcriptomic information further demonstrate the increasing scale of combined molecular datasets, strengthening opportunities in biomarker discovery, drug development and translational oncology.

Challenges in United States FFPE Tissue Samples for Genomics Study and Analysis Market

Standardization Across Pre-Analytical Conditions and High-Complexity Assays

A major challenge is obtaining reproducible results across tissue specimens prepared under different fixation, storage and sectioning conditions. Genomic assays increasingly interrogate hundreds of genes—Tempus xT CDx, for example, evaluates 648 genes—while emerging spatial approaches operate across millions of cells per slide. Clinical implementation also demands validation: the 623-specimen infectious-pathology FFPE study incorporated orthogonal approaches such as species-specific PCR and immunohistochemistry where possible. Consequently, scaling from targeted PCR toward broad NGS, WGS and transcriptomic workflows increases requirements for sample qualification, laboratory controls and computational interpretation.

United States FFPE Tissue Samples for Genomics Study and Analysis Market Segmentation

Sample-type revenues total USD 285.25 million in 2026, with blocks holding approximately 30.14%, scrolls 23.47%, slides 19.99%, curls 11.39%, sections 8.21%, and other cores/punches 6.80%. By downstream nucleic acid, DNA-based analysis contributes approximately 63.70% of the USD 285.10 million 2026 total, compared with approximately 36.30% for RNA-based workflows.

By Sample Type

Blocks are the largest supplied sample category, increasing from USD 81.68 million in 2025 to USD 85.98 million in 2026 and USD 129.68 million by 2034. This corresponds to a 5.27% CAGR and approximately 30.14% of the 2026 sample-type total. Scrolls rank second at USD 66.95 million in 2026 and USD 97.34 million by 2034, while slides reach USD 57.02 million and USD 83.28 million, respectively.

Blocks are also the fastest-growing supplied sample type at 5.27% CAGR, followed by curls at 5.20%, others at 4.99%, slides at 4.85%, sections at 4.84%, and scrolls at 4.79%. Curls increase from USD 32.50 million in 2026 to USD 48.75 million in 2034, while sections rise from USD 23.41 million to USD 34.17 million.

By Nucleic Acid Type (Downstream Application)

DNA-based genomic analysis is the dominant category, valued at USD 181.60 million in 2026 compared with USD 173.17 million in 2025 and projected to reach USD 265.66 million by 2034 at 4.87% CAGR. It accounts for approximately 63.70% of the supplied 2026 nucleic-acid total and encompasses WGS, WES, CNV/SNP analysis and qPCR-based genotyping.

RNA-based genomic analysis is the faster-growing category at 5.11% CAGR, rising from USD 103.50 million in 2026 to USD 154.21 million by 2034. Its approximately 36.30% contribution in 2026 reflects demand for transcriptome profiling, mRNA sequencing, miRNA sequencing and gene-fusion studies, while DNA workflows retain the larger absolute revenue base.

By Technology

Technology segmentation encompasses NGS, microarrays, PCR/qPCR, digital PCR, Sanger sequencing, NanoString and other platforms. The mandatory dataset does not assign technology-specific revenues or CAGRs; consequently, no unsupported technology market values are introduced. At the broader level, the supplied market total rises from USD 285.25 million in 2026 to USD 421.85 million in 2034 at 4.99% CAGR.

NGS is structurally important because WGS, WES, transcriptomic and large-panel profiling increasingly require massively parallel sequencing. PCR/qPCR and dPCR remain complementary for targeted validation and lower-plex testing. Technology-specific leadership and fastest-growth CAGRs cannot be numerically ranked from the supplied tables without introducing unsupported estimates.

By Application

Applications include cancer genomics, infectious-disease genomics, neurological genomics, rare-disease research, pharmacogenomics, biomarker discovery and population-health studies. Cancer genomics has substantial commercial relevance given tissue-based comprehensive profiling such as the 648-gene xT CDx assay, while infectious-disease feasibility is illustrated by the 623-FFPE-specimen metagenomic study.

No application-level market values or CAGRs were provided in the mandatory tables, preventing quantitative designation of the largest and fastest-growing application. Across all applications, however, the supplied national total advances from USD 271.64 million in 2025 to USD 285.25 million in 2026 and USD 421.85 million in 2034.

By End User

Academic and research institutes, CROs, biopharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, and biobanks/tissue repositories constitute the principal end-user groups. Their workflows range from small targeted studies to databases containing millions of molecular records; Tempus, for example, reports more than 1.5 million clinical records linked with genomic information within a research library exceeding 40 million records.

The supplied tables do not allocate USD values or CAGRs by end user, so an unsupported largest or fastest-growing category is not assigned. Collectively, end-user expenditure is represented by the national sample-type total of USD 285.25 million in 2026, projected to reach USD 421.85 million by 2034 at 4.99% CAGR.

United States FFPE Tissue Samples for Genomics Study and Analysis Market Counties Outlook

The mandatory dataset provides only a United States national total and contains no county-, state-, Census-region-, or metropolitan-level allocation. Accordingly, the defensible geographic benchmark remains USD 285.25 million nationally in 2026, rising to USD 421.85 million in 2034 at 4.99% CAGR. Assigning percentage shares to California, Massachusetts, New York, Texas or individual counties would require geographic source data not included in the mandatory tables and therefore would conflict with the requirement not to alter or invent supplied market values.

Geographic demand nevertheless spans major U.S. academic medical centers, pathology laboratories, biobanks, CRO clusters and biotechnology hubs. At the national level, sample activity is split approximately 30.14% blocks, 23.47% scrolls, 19.99% slides, 11.39% curls, 8.21% sections and 6.80% other cores/punches in 2026. DNA-oriented downstream analysis contributes approximately 63.70% versus 36.30% for RNA-oriented analysis, providing the supported sector split for the U.S. geographic outlook.

Top players in United States FFPE Tissue Samples for Genomics Study and Analysis Market

1. Thermo Fisher Scientific
2. Illumina
3. QIAGEN
4. Roche
5. Foundation Medicine
6. Tempus AI
7. Caris Life Sciences
8. Labcorp
9. Quest Diagnostics
10. NeoGenomics Laboratories
11. Agilent Technologies
12. Bio-Rad Laboratories
13. NanoString Technologies
14. Fulgent Genetics
15. Guardant Health

Top Two Companies

• Illumina:Public information reviewed for this report does not disclose an audited percentage of U.S. FFPE-sample revenue attributable specifically to Illumina, so a market-share percentage is not fabricated. Its positioning is nevertheless significant in sequencing infrastructure: in February 2025 the company announced multiomic technologies spanning genomics, spatial transcriptomics, single-cell analysis, CRISPR and methylation, including spatial analysis across millions of cells per slide, a 9-fold larger capture area and 4-fold greater resolution. Its April 2025 collaboration with Tempus additionally targets broader clinical adoption of NGS and genomic AI.
• Thermo Fisher Scientific:A directly comparable percentage of U.S. FFPE-sample revenue is likewise not publicly established in the sources reviewed and is therefore not assigned. The company maintains positioning across sequencing, PCR, nucleic-acid preparation and molecular-analysis workflows. Evidence of clinical FFPE utility includes a 623-sample pathology investigation that used Thermo Fisher's Ion Torrent sequencing platform alongside QIAGEN's CLC Genomics Workbench. The study covered specimens analyzed between November 2021 and April 2025 and incorporated PCR and immunohistochemistry for orthogonal confirmation where possible, demonstrating the relevance of integrated sequencing and validation ecosystems.

Recent Developments in United States FFPE Tissue Samples for Genomics Study and Analysis Market

• 2026:Tempus received FDA approval for a tumor-only indication for xT CDx, its 648-gene tissue-based NGS assay, enabling profiling when matched blood or saliva is unavailable.
• 2025:Illumina announced a multiomics roadmap spanning genomics, spatial transcriptomics, single-cell, CRISPR and methylation technologies, including a planned 2026 5-base workflow.
• 2025:Tempus introduced its Fuses program leveraging more than 40 million research records, including over 1.5 million records linked with genomic information and approximately 300,000 genomic/whole-transcriptomic records.
• 2025:Illumina and Tempus announced a collaboration designed to accelerate clinical adoption of NGS through genomic AI and multimodal evidence generation.
• 2025:Foundation Medicine expanded its U.S. genomic testing portfolio through a Fulgent Genetics partnership, with FoundationOne Germline and FoundationOne Germline More becoming available for ordering alongside comprehensive genomic profiling tests from February 28, 2025.

Research Methodology

The analysis uses the supplied mandatory numerical tables as the primary quantitative source for 2025, 2026 and 2034 values, percentage contributions and CAGR calculations. Segment percentages were calculated directly from supplied totals: for example, USD 85.98 million divided by USD 285.25 million produces approximately 30.14% for blocks, while USD 181.60 million divided by USD 285.10 million produces approximately 63.70% for DNA-based analysis. External sources were used only for qualitative technology, company and recent-development evidence; no external source was allowed to overwrite the supplied USD 271.64 million 2025 total, USD 285.25 million 2026 sample-type total, USD 421.85 million 2034 forecast or 4.99% CAGR. Where technology-, application-, end-user-, company-share- or county-level numerical data were absent, values were explicitly left undisclosed rather than estimated.